{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:15:59Z","timestamp":1788916559050,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.euroneuro.2004.12.002","type":"journal-article","created":{"date-parts":[[2005,3,15]],"date-time":"2005-03-15T12:21:42Z","timestamp":1110889302000},"page":"279-282","source":"Crossref","is-referenced-by-count":10,"title":["Anxiogenic effects of Sumatriptan in panic disorder: A double-blind, placebo-controlled study"],"prefix":"10.1016","volume":"15","author":[{"given":"Daniella","family":"Amital","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Fostick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Sasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Amital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Zohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2004.12.002_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0165-1781(90)90096-N","article-title":"Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder","volume":"31","author":"den Boer","year":"1990","journal-title":"Psychiatry. Res."},{"key":"10.1016\/j.euroneuro.2004.12.002_bib2","first-page":"65","article-title":"Diagnostic aspects of anxiety disorders","volume":"90","author":"den Boer","year":"1990","journal-title":"Acta Psychiatr. Belg."},{"key":"10.1016\/j.euroneuro.2004.12.002_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02245749","article-title":"Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin","volume":"102","author":"den Boer","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2004.12.002_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1176\/ajp.146.2.148","article-title":"A neuroanatomical hypothesis for panic disorder","volume":"146","author":"Gorman","year":"1989","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2004.12.002_bib5","unstructured":"Gross-Isseroff, R.G., Cohen, R., Sasson, Y., Voet, H. Zohar, J. Serotinergic dissection of obsessive compulsive symptoms: a challenge study with mCPP and Sumatriptan. Submitted for publication."},{"key":"10.1016\/j.euroneuro.2004.12.002_bib6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00216062","article-title":"Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder","volume":"96","author":"Kahn","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2004.12.002_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0006-3223(88)90091-1","article-title":"Serotonin and anxiety revisited","volume":"23","author":"Kahn","year":"1988","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2004.12.002_bib8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF00449808","article-title":"The utility of the panic disorder concept","volume":"238","author":"Klein","year":"1989","journal-title":"Eur. Arch. Psychiatr. Neurol. Sci."},{"key":"10.1016\/j.euroneuro.2004.12.002_bib9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0924-977X(01)00082-7","article-title":"Sumatriptan, 5-HT1D receptors and obsessive\u2013compulsive disorder","volume":"11","author":"Koran","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2004.12.002_bib10","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1176\/ajp.153.11.1505a","article-title":"Sumatriptan and panic-like symptoms","volume":"153","author":"Loi","year":"1996","journal-title":"Am. J. Psychatr."},{"key":"10.1016\/j.euroneuro.2004.12.002_bib11","first-page":"268","article-title":"Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile","volume":"42","author":"Meltzer","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.euroneuro.2004.12.002_bib12","first-page":"3","article-title":"Central serotonin receptors. Principal fundamental and functional aspects. Therapeutic applications","volume":"150","author":"Moulignier","year":"1994","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.euroneuro.2004.12.002_bib13","first-page":"53","article-title":"A comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety","volume":"51","author":"Murphy","year":"1990","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2004.12.002_bib14","doi-asserted-by":"crossref","first-page":"91S","DOI":"10.1097\/00004714-199006001-00016","article-title":"Obsessive\u2013compulsive disorder: treatment with serotonin-selective uptake inhibitors, azapirones, and other agents","volume":"10","author":"Murphy","year":"1990","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2004.12.002_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s002130050777","article-title":"Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder","volume":"140","author":"Pian","year":"1998","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2004.12.002_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/da.10126","article-title":"Obsessive\u2013compulsive spectrum conditions in obsessive\u2013compulsive disorder and other anxiety disorders","volume":"18","author":"Richter","year":"2003","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2004.12.002_bib17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0278-5846(99)00051-2","article-title":"Single photon emission computed tomography of the brain with Tc-99 m HMPAO during sumatriptan challenge in obsessive\u2013compulsive disorder: investigating the functional role of the serotonin auto-receptor","volume":"23","author":"Stein","year":"1999","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2004.12.002_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0006-3223(90)90428-5","article-title":"Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder","volume":"28","author":"Targum","year":"1990","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2004.12.002_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0165-1781(90)90125-O","article-title":"Mechanisms of anxiogenic vulnerability in panic disorder","volume":"31","author":"Targum","year":"1990","journal-title":"Psychiatry. Res."},{"key":"10.1016\/j.euroneuro.2004.12.002_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1023\/A:1015147920283","article-title":"Frequent blood\u2013brain barrier disruption in the human cerebral cortex","volume":"21","author":"Tomkins","year":"2001","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.euroneuro.2004.12.002_bib21","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/archpsyc.1987.01800230026006","article-title":"Serotonergic responsivity in obsessive compulsive disorder: comparison of patients and healthy controls","volume":"44","author":"Zohar","year":"1987","journal-title":"Arch. Gen. Psychiatry."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X04002020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X04002020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T03:29:59Z","timestamp":1548646199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X04002020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0924977X04002020"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2004.12.002","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}